Published in Br J Cancer on June 01, 1994
Systematic reviews of evaluations of prognostic variables. BMJ (2001) 6.69
REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer (2005) 4.85
Review of survival analyses published in cancer journals. Br J Cancer (1995) 4.10
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med (2012) 3.62
Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer (2004) 3.15
Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med (2013) 2.23
Prognostic models for predicting death after hepatectomy in individuals with hepatic metastases from colorectal cancer. World J Surg (2008) 2.15
Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One (2012) 2.14
Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Br J Cancer (2003) 2.08
Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol (2012) 2.05
External validity of risk models: Use of benchmark values to disentangle a case-mix effect from incorrect coefficients. Am J Epidemiol (2010) 2.03
Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res (2004) 1.96
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med (2012) 1.85
A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group. Arch Dis Child (1996) 1.81
Survival analysis part IV: further concepts and methods in survival analysis. Br J Cancer (2003) 1.77
Reporting methods in studies developing prognostic models in cancer: a review. BMC Med (2010) 1.68
Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol (2007) 1.59
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer (2009) 1.53
Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med (2010) 1.47
Predicting developmental delay in a longitudinal cohort of preschool children with single-suture craniosynostosis: is neurobehavioral assessment important? Dev Med Child Neurol (2014) 1.40
Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer (1996) 1.39
Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer (1998) 1.38
Individual participant data meta-analysis for a binary outcome: one-stage or two-stage? PLoS One (2013) 1.34
Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer (2009) 1.31
Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer (1995) 1.30
Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG). Br J Cancer (1999) 1.26
A new prognostic staging system for rectal cancer. Ann Surg (2004) 1.26
Patient-centered yes/no prognosis using learning machines. Int J Data Min Bioinform (2008) 1.26
Community survey of factors associated with consultation for low back pain. BMJ (1998) 1.26
Sample size: how many patients are necessary? Br J Cancer (1995) 1.15
Meta-analysis in medical research. Hippokratia (2010) 1.14
pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br J Cancer (1996) 1.11
Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors. Br J Cancer (2001) 1.10
Development and Validation of Biomarker Classifiers for Treatment Selection. J Stat Plan Inference (2008) 1.10
p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. J Clin Pathol (2003) 1.09
Artificial intelligence for clinicians. J R Soc Med (1999) 1.08
Characterizing mammographic images by using generic texture features. Breast Cancer Res (2012) 1.07
Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Syst Rev (2013) 1.06
Analysis of DNA microarray expression data. Best Pract Res Clin Haematol (2009) 1.03
Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer (2000) 1.02
Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer (1996) 1.02
STRengthening analytical thinking for observational studies: the STRATOS initiative. Stat Med (2014) 1.01
Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol (2000) 0.98
Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer (1996) 0.97
Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med (2012) 0.97
Prognostic implications of qualitative assessment of left ventricular function compared to simple routine quantitative echocardiography. Heart (1997) 0.96
Vascular grading of angiogenesis: prognostic significance in breast cancer. Br J Cancer (2000) 0.95
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw (2011) 0.95
How best to express oestrogen receptor activity. Br J Cancer (1996) 0.94
Proteomics and biomarkers in clinical trials for drug development. J Proteomics (2011) 0.94
Value of predictive instruments to determine persisting restriction of function in patients with subacute non-specific low back pain. Systematic review. Eur Spine J (2007) 0.94
Suboptimal analysis using 'optimal' cutpoints. Br J Cancer (1998) 0.93
Risk Factors for Endometriosis in a German Case-Control Study. Geburtshilfe Frauenheilkd (2011) 0.92
Lymphatic vessel density and prognosis in cutaneous melanoma. Br J Cancer (2004) 0.92
An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma. Br J Cancer (2006) 0.91
Proteomics as a guiding tool for more effective personalized therapy. Ann Oncol (2010) 0.91
Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort. Radiat Oncol (2013) 0.90
Meta-analyses of randomised trials: when the whole is more than just the sum of the parts. Br J Cancer (1996) 0.90
The importance of identifying and validating prognostic factors in oncology. Semin Oncol (2010) 0.90
Statistical challenges in the development and evaluation of marker-based clinical tests. BMC Med (2012) 0.89
Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer (1995) 0.88
Long noncoding RNAs as novel predictors of survival in human cancer: a systematic review and meta-analysis. Mol Cancer (2016) 0.87
Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients. Br J Cancer (2003) 0.87
Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer (2006) 0.87
Guidelines for development of diagnostic markers in bladder cancer. World J Urol (2008) 0.86
Study designs and statistical analyses for biomarker research. Sensors (Basel) (2012) 0.86
Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol (2013) 0.86
Prostate cancer: serum and tissue markers. Rev Urol (2001) 0.85
Development and progression of colorectal neoplasia. Cancer Biomark (2010) 0.85
Predicting survival outcomes using subsets of significant genes in prognostic marker studies with microarrays. BMC Bioinformatics (2006) 0.84
Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studies. Br J Cancer (2014) 0.84
Prospective evaluation of prognostic factors in operable breast cancer. Br J Cancer (1996) 0.83
Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. Curr Oncol Rep (2011) 0.83
A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma. Nat Commun (2015) 0.83
Sample size matters: a guide for surgeons. World J Surg (2005) 0.82
Prognostic significance of Cdx2 immunohistochemical expression in gastric cancer: a meta-analysis of published literatures. J Exp Clin Cancer Res (2012) 0.81
Intensity of tumor budding as an index for the malignant potential in invasive rectal carcinoma. Cancer Res Treat (2005) 0.81
Predicting infectious complications in neutropenic children and young people with cancer (IPD protocol). Syst Rev (2012) 0.80
Predicting Clinical Outcomes Using Molecular Biomarkers. Biomark Cancer (2016) 0.79
Challenges in clinical studies with multiple imaging probes. Nucl Med Biol (2007) 0.79
Prognostic value of cancer stem cell marker CD133 expression in esophageal carcinoma: A meta-analysis. Mol Clin Oncol (2015) 0.78
Accuracy of typing and grading invasive mammary carcinomas on core needle biopsy compared with the excisional specimen. Virchows Arch (2004) 0.78
Self-rated health status as a predictor of death, functional and cognitive impairment: a longitudinal cohort study. Eur J Ageing (2006) 0.78
A decision-analytic approach to define poor prognosis patients: a case study for non-seminomatous germ cell cancer patients. BMC Med Inform Decis Mak (2008) 0.77
Prognostic significance of STAT3/phosphorylated-STAT3 in tumor: a meta-analysis of literatures. Int J Clin Exp Med (2015) 0.77
Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcome. Br J Cancer (1998) 0.76
Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Br J Cancer (2015) 0.76
Mammographic Density and Prediction of Nodal Status in Breast Cancer Patients. Geburtshilfe Frauenheilkd (2013) 0.76
Methodological issues in current practice may lead to bias in the development of biomarker combinations for predicting acute kidney injury. Kidney Int (2016) 0.75
Hormone Therapy and its Effect on the Prognosis in Breast Cancer Patients. Geburtshilfe Frauenheilkd (2015) 0.75
Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review. Ont Health Technol Assess Ser (2016) 0.75
Developing a new reference standard: is validation necessary? Acad Radiol (2010) 0.75
Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design. Acad Radiol (2017) 0.75
Prognostic risk factors of early gastric cancer-a western experience. Langenbecks Arch Surg (2016) 0.75
Do paraneoplastic changes in diffuse FDG organ uptake predict relapse? - Wait for confirmation study : Reply to Jorgov et al. Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1220--30. Eur J Nucl Med Mol Imaging (2017) 0.75
Flexible regression models with cubic splines. Stat Med (1989) 14.45
Some thoughts on clinical trials, especially problems of multiplicity. Science (1977) 4.08
Testing for qualitative interactions between treatment effects and patient subsets. Biometrics (1985) 3.71
Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst (1988) 3.09
Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep (1985) 2.76
Confidence intervals for reporting results of clinical trials. Ann Intern Med (1986) 2.49
Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst (1991) 2.29
Measures of explained variation for survival data. Stat Med (1990) 2.06
Bootstrap investigation of the stability of a Cox regression model. Stat Med (1989) 1.91
An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer (1990) 1.83
Causality inference in observational vs. experimental studies. An empirical comparison. Am J Epidemiol (1988) 1.76
Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat (1992) 1.74
Head and neck sarcomas: prognostic factors and implications for treatment. Br J Cancer (1993) 1.67
Categorising continuous variables. Br J Cancer (1991) 1.62
Comparison of the Cox model and the regression tree procedure in analysing a randomized clinical trial. Stat Med (1993) 1.55
The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med (1978) 1.54
A score at diagnosis for predicting length of remission in childhood acute lymphoblastic leukaemia. Br J Cancer (1980) 1.47
Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst (1993) 1.37
A proposal for examining and reporting stepwise regressions. Stat Med (1991) 1.26
Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol (1982) 1.23
When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol (1991) 1.20
Bayesian subset analysis in a colorectal cancer clinical trial. Stat Med (1992) 1.19
Prognostic value of continuous variables in breast cancer and head and neck cancer. Dependence on the cut-off level. Br J Cancer (1988) 1.17
The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer (1985) 1.15
Evaluating serial cancer marker studies in patients at risk of recurrent disease. Biometrics (1981) 1.11
Analysis of clinical trial outcomes: some comments on subgroup analyses. Control Clin Trials (1989) 1.09
The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. Int J Gynecol Cancer (1993) 1.06
Adjusting survival curves for imbalances in prognostic factors. Br J Cancer (1988) 1.02
Is DNA flow cytometry a useful investigation in breast cancer? Eur J Cancer (1992) 1.01
Identification and assessment of prognostic factors. Semin Oncol (1988) 0.96
Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis. Br J Cancer (1993) 0.94
Flexible covariate effects in the proportional hazards model. Breast Cancer Res Treat (1992) 0.91
Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring. Br J Cancer (1993) 0.84
Statistical methods for assessing agreement between two methods of clinical measurement. Lancet (1986) 211.50
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA (1995) 45.41
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet (2001) 31.74
Measuring agreement in method comparison studies. Stat Methods Med Res (1999) 31.11
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Multiple significance tests: the Bonferroni method. BMJ (1995) 23.46
Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ (2001) 20.65
Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed) (1986) 18.51
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics (1975) 18.25
Analysis of serial measurements in medical research. BMJ (1990) 16.69
Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (2000) 15.53
Flexible regression models with cubic splines. Stat Med (1989) 14.45
Cronbach's alpha. BMJ (1997) 13.79
The scandal of poor medical research. BMJ (1994) 11.58
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med (2001) 11.48
Statistical guidelines for contributors to medical journals. Br Med J (Clin Res Ed) (1983) 10.90
Statistics notes. Logarithms. BMJ (1996) 10.56
Statistics in medical journals. Stat Med (1983) 9.80
Evaluating non-randomised intervention studies. Health Technol Assess (2003) 9.69
The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 9.40
Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet (1995) 9.14
Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ (2001) 8.98
Statistics and ethics in medical research: III How large a sample? Br Med J (1980) 8.78
Signaling of cell fate decisions by CLAVATA3 in Arabidopsis shoot meristems. Science (1999) 8.61
Data management and analysis for gene expression arrays. Nat Genet (1998) 8.60
Better reporting of randomised controlled trials: the CONSORT statement. BMJ (1996) 8.39
More informative abstracts revisited. Ann Intern Med (1990) 8.26
The CONSTANS gene of Arabidopsis promotes flowering and encodes a protein showing similarities to zinc finger transcription factors. Cell (1995) 7.76
Transforming data. BMJ (1996) 6.78
Regression towards the mean. BMJ (1994) 6.57
Measurement error. BMJ (1996) 6.18
Dependence of stem cell fate in Arabidopsis on a feedback loop regulated by CLV3 activity. Science (2000) 6.05
Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA (1994) 5.80
Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion (1999) 5.67
Statistics notes. The odds ratio. BMJ (2000) 5.61
Plasmid vectors for the genetic analysis and manipulation of rhizobia and other gram-negative bacteria. Methods Enzymol (1986) 5.58
The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol (2001) 5.43
Applying the right statistics: analyses of measurement studies. Ultrasound Obstet Gynecol (2003) 5.40
High frequency mobilization of gram-negative bacterial replicons by the in vitro constructed Tn5-Mob transposon. Mol Gen Genet (1984) 5.35
How can medical journals help prevent poor medical research? Some opportunities presented by electronic publishing. Lancet (1999) 5.27
Statistics notes. Interaction 2: Compare effect sizes not P values. BMJ (1996) 5.18
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol (1996) 5.09
Correlation, regression, and repeated data. BMJ (1994) 4.88
Calculating correlation coefficients with repeated observations: Part 1--Correlation within subjects. BMJ (1995) 4.87
REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer (2005) 4.85
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
Social factors and height of primary schoolchildren in England and Scotland. J Epidemiol Community Health (1978) 4.73
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res (1998) 4.68
Randomisation. BMJ (1991) 4.66
Patients' preferences and randomised trials. Lancet (1996) 4.64
The potential for improved teamwork to reduce medical errors in the emergency department. The MedTeams Research Consortium. Ann Emerg Med (1999) 4.59
Measurement error and correlation coefficients. BMJ (1996) 4.38
Indirect comparisons of competing interventions. Health Technol Assess (2005) 4.33
Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst (1998) 4.32
Measurement error. BMJ (1996) 4.13
Survival analysis part I: basic concepts and first analyses. Br J Cancer (2003) 4.08
Some examples of regression towards the mean. BMJ (1994) 4.01
Survival probabilities (the Kaplan-Meier method). BMJ (1998) 3.98
Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol (2007) 3.84
Bayesian variable selection method for censored survival data. Biometrics (1998) 3.84
A catalogue of reporting guidelines for health research. Eur J Clin Invest (2010) 3.83
Testing for qualitative interactions between treatment effects and patient subsets. Biometrics (1985) 3.71
A molecular link between stem cell regulation and floral patterning in Arabidopsis. Cell (2001) 3.55
Effects of a drug overdose in a television drama on presentations to hospital for self poisoning: time series and questionnaire study. BMJ (1999) 3.52
Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists. BMJ (2011) 3.50
The benefits and harms of breast cancer screening: an independent review. Br J Cancer (2013) 3.43
Transformations, means, and confidence intervals. BMJ (1996) 3.42
Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep (1978) 3.38
Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ (1995) 3.35
Measurement error proportional to the mean. BMJ (1996) 3.34
National study of health and growth: standards of attained height, weight and triceps skinfold in English children 5 to 11 years old. Ann Hum Biol (1977) 3.23
Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery (1986) 3.22
The use of transformation when comparing two means. BMJ (1996) 3.22
Randomized phase II clinical trials. Cancer Treat Rep (1985) 3.19
A note on the use of the intraclass correlation coefficient in the evaluation of agreement between two methods of measurement. Comput Biol Med (1990) 3.18
Interaction 3: How to examine heterogeneity. BMJ (1996) 3.17
Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer (2004) 3.15
Survival analysis part II: multivariate data analysis--an introduction to concepts and methods. Br J Cancer (2003) 3.06
A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst (2000) 2.95
Calculating correlation coefficients with repeated observations: Part 2--Correlation between subjects. BMJ (1995) 2.94
Randomised trial of educational visits to enhance use of systematic reviews in 25 obstetric units. BMJ (1998) 2.94
A new family of RSF1010-derived expression and lac-fusion broad-host-range vectors for gram-negative bacteria. Gene (1990) 2.89
Outcome selection bias in meta-analysis. Stat Methods Med Res (2005) 2.86
Statistics and ethics in medical research. VI--Presentation of results. Br Med J (1980) 2.85
Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol (2001) 2.82
Demonstration of high-fidelity simulation team training for emergency medicine. Acad Emerg Med (1999) 2.82
The effects of combining education and enforcement to reduce tobacco sales to minors. A study of four northern California communities. JAMA (1991) 2.77
A prognostic model for ovarian cancer. Br J Cancer (2001) 2.77
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. J Am Podiatr Med Assoc (2001) 2.71
Survival analysis Part III: multivariate data analysis -- choosing a model and assessing its adequacy and fit. Br J Cancer (2003) 2.71
Extension of the host range of Escherichia coli vectors by incorporation of RSF1010 replication and mobilization functions. J Bacteriol (1985) 2.70
Baseline comparisons in randomized clinical trials. Stat Med (1991) 2.69
Predictors of physician's smoking cessation advice. JAMA (1991) 2.66
More informative abstracts. Ann Intern Med (1987) 2.63
Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet (2001) 2.61
One and two sided tests of significance. BMJ (1994) 2.61
Simulation based teamwork training for emergency department staff: does it improve clinical team performance when added to an existing didactic teamwork curriculum? Qual Saf Health Care (2004) 2.60
Confidence intervals for reporting results of clinical trials. Ann Intern Med (1986) 2.49